|
| |
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
Journal of Experimental Biology, Vol 196, Issue 1 251-262, Copyright © 1994 by Company of Biologists
JOURNAL ARTICLES |
JP Henry, D Botton, C Sagne, MF Isambert, C Desnos, V Blanchard, R Raisman-Vozari, E Krejci, J Massoulie and B Gasnier
CNRS URA 1112, Neurobiologie Physico-Chimique, Institut de Biologie Physico-Chimique, Paris, France.
Prior to secretion, monoamines (catecholamines, serotonin, histamine) are concentrated from the cytoplasm into vesicles by vesicular monoamine transporters (VMAT). These transporters also carry non-physiological compounds, e.g. the neurotoxin methyl-4-phenylpyridinium. VMAT acts as an electrogenic antiporter (exchanger) of protons and monoamines, using a proton electrochemical gradient. Vesicular transport is inhibited by specific ligands, including tetrabenazine, ketanserin and reserpine. The mechanism of transport and the biochemistry of VMAT have been analyzed with the help of these tools, using mainly the chromaffin granules from bovine adrenal glands as a source of transporter. Although biochemical studies did not suggest a multiplicity of VMATs, two homologous but distinct VMAT genes have recently been cloned from rat, bovine and human adrenal glands. The VMAT proteins are predicted to possess 12 transmembrane segments, with both extremities lying on the cytoplasmic side. They possess N-glycosylation sites in a putative luminal loop and phosphorylation sites in cytoplasmic domains. In rat, VMAT1 is expressed in the adrenal gland whereas VMAT2 is expressed in the brain. In contrast, we found that the bovine adrenal gland expressed both VMAT1 and VMAT2. VMAT2 corresponds to the major transporter of chromaffin granules, as shown by partial peptidic sequences of the purified protein and by a pharmacological analysis of the transport obtained in transfected COS cells (COS cells are monkey kidney cells possessing the ability to replicate SV-40-origin-containing plasmids). We discuss the possibility that VMAT1 may be specifically addressed to large secretory granules vesicles, whereas VMAT2 may also be addressed to small synaptic vesicles; species differences would then reflect the distinct physiological roles of the small synaptic vesicles in the adrenal gland.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Kvetnansky, E. L. Sabban, and M. Palkovits Catecholaminergic Systems in Stress: Structural and Molecular Genetic Approaches Physiol Rev, April 1, 2009; 89(2): 535 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gopalakrishnan, M. Sievert, and A. E. Ruoho Identification of the Substrate Binding Region of Vesicular Monoamine Transporter-2 (VMAT-2) Using Iodoaminoflisopolol as a Novel Photoprobe Mol. Pharmacol., December 1, 2007; 72(6): 1567 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Murase and R. D. McKay A specific survival response in dopamine neurons at most risk in Parkinson's disease. J. Neurosci., September 20, 2006; 26(38): 9750 - 9760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Wimalasena and K. Wimalasena Kinetic Evidence for Channeling of Dopamine between Monoamine Transporter and Membranous Dopamine-{beta}-monooxygenase in Chromaffin Granule Ghosts J. Biol. Chem., April 9, 2004; 279(15): 15298 - 15304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Machado, J. F. Gomez, G. Betancor, M. Camacho, M. A. Brioso, and R. Borges Hydralazine Reduces the Quantal Size of Secretory Events by Displacement of Catecholamines From Adrenomedullary Chromaffin Secretory Vesicles Circ. Res., November 1, 2002; 91(9): 830 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Machado, A. Morales, J. F. Gomez, and R. Borges cAMP Modulates Exocytotic Kinetics and Increases Quantal Size in Chromaffin Cells Mol. Pharmacol., September 1, 2001; 60(3): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gerhard, N. Neumayer, E. Presecan-Siedel, R. Zanner, E. Lengyel, T. Cramer, M. Hocker, and C. Prinz Gastrin Induces Expression and Promoter Activity of the Vesicular Monoamine Transporter Subtype 2 Endocrinology, August 1, 2001; 142(8): 3663 - 3672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. EIDEN The vesicular neurotransmitter transporters: current perspectives and future prospects FASEB J, December 1, 2000; 14(15): 2396 - 2400. [Full Text]
|
|
|
|
|
|
G. R. UHL, S. LI, N. TAKAHASHI, K. ITOKAWA, Z. LIN, M. HAZAMA, and I. SORA The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins FASEB J, December 1, 2000; 14(15): 2459 - 2465. [Abstract] [Full Text]
|
|
|
|
|
|
W. Y. Lee, J. W. Chang, N. L. Nemeth, and U. J. Kang Vesicular Monoamine Transporter-2 and Aromatic L-Amino Acid Decarboxylase Enhance Dopamine Delivery after L-3,4-Dihydroxyphenylalanine Administration in Parkinsonian Rats J. Neurosci., April 15, 1999; 19(8): 3266 - 3274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Takahashi, L. L. Miner, I. Sora, H. Ujike, R. S. Revay, V. Kostic, V. Jackson-Lewis, S. Przedborski, and G. R. Uhl VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity PNAS, September 2, 1997; 94(18): 9938 - 9943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Parmer, M. Mahata, S. Mahata, M. T. Sebald, D. T. O'Connor, and L. A. Miles Tissue Plasminogen Activator (t-PA) Is Targeted to the Regulated Secretory Pathway. CATECHOLAMINE STORAGE VESICLES AS A RESERVOIR FOR THE RAPID RELEASE OF t-PA J. Biol. Chem., January 17, 1997; 272(3): 1976 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gualix, M. Abal, J. Pintor, F. Garcia-Carmona, and M. T. Miras-Portugal Nucleotide Vesicular Transporter of Bovine Chromaffin Granules J. Biol. Chem., January 26, 1996; 271(4): 1957 - 1965. [Abstract] [Full Text] [PDF]
|
|
